A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Study to Evaluate Impact of Sunobinop (V117957) on Alcohol Consumption in Subjects Diagnosed With Moderate to Severe Alcohol Use Disorder and Seeking Treatment
Latest Information Update: 30 May 2025
At a glance
- Drugs Sunobinop (Primary)
- Indications Alcoholism
- Focus Therapeutic Use
- Sponsors Imbrium Therapeutics
Most Recent Events
- 18 Nov 2024 Planned number of patients changed from 200 to 240.
- 18 Nov 2024 According to Imbrium Therapeutics media release, company announced the first patient has been randomized and dosed in this study.
- 18 Oct 2024 Status changed from not yet recruiting to recruiting.